Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Kota Tange"'
Autor:
Jessica Anindita, Hiroki Tanaka, Ryotaro Oyama, Shinya Hagiwara, Daiki Shirane, Sakura Taneichi, Yuta Nakai, Kota Tange, Hiroto Hatakeyama, Yu Sakurai, Hidetaka Akita
Publikováno v:
Pharmaceutics, Vol 15, Iss 12, p 2702 (2023)
Because of its efficient and robust gene transfer capability, messenger RNA (mRNA) has become a promising tool in various research fields. The lipid nanoparticle (LNP) is considered to be a fundamental technology for an mRNA delivery system and has b
Externí odkaz:
https://doaj.org/article/928e771d58a540ed8ba2ff73efc70014
Autor:
Masaki Gomi, Yuka Nakayama, Yu Sakurai, Ryotaro Oyama, Koki Iwasaki, Mizuki Doi, Yi Liu, Mizuho Hori, Himeka Watanabe, Kohei Hashimoto, Hiroki Tanaka, Kota Tange, Yuta Nakai, Hidetaka Akita
Publikováno v:
Pharmaceuticals, Vol 16, Iss 9, p 1270 (2023)
Multiple sclerosis is a disease caused by autoantigen-responsive immune cells that disrupt the myelin in the central nervous system (CNS). Although immunosuppressive drugs are used to suppress symptoms, no definitive therapy exists. As in the experim
Externí odkaz:
https://doaj.org/article/c8e2dc1066954f429292f5e51e38472b
Autor:
Daiki Shirane, Hiroki Tanaka, Yu Sakurai, Sakura Taneichi, Yuta Nakai, Kota Tange, Itsuko Ishii, Hidetaka Akita
Publikováno v:
Pharmaceutics, Vol 15, Iss 7, p 1819 (2023)
The lipid nanoparticle (LNP) is one of the promising nanotechnologies for the delivery of RNA molecules, such as small interfering RNA (siRNA) and messenger RNA (mRNA). A series of LNPs that contain an mRNA encoding the antigen protein of SARS-CoV-2
Externí odkaz:
https://doaj.org/article/a7474de252654456bfef9cf26ae6de09
Autor:
Tomomi Akita, Kazuaki Oda, Satoru Narukawa, Yuki Morita, Kota Tange, Yuta Nakai, Chikamasa Yamashita
Publikováno v:
Pharmaceuticals, Vol 16, Iss 6, p 838 (2023)
Chronic obstructive pulmonary disease (COPD) results in obstructive ventilatory impairment caused by emphysema, and current treatment is limited to symptomatic therapy or lung transplantation. Therefore, the development of new treatments to repair al
Externí odkaz:
https://doaj.org/article/58fad632906f493a9059358d1445260e
Autor:
Tomomi Akita, Yuki Morita, Takehiro Kawai, Kazuaki Oda, Kota Tange, Yuta Nakai, Chikamasa Yamashita
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 37 (2022)
Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis and emphysema, and current drug treatments target its symptoms. Thus, the development of a therapeutic drug to repair alveolar destruction is urgently needed. Our pre
Externí odkaz:
https://doaj.org/article/daaa5c829bf14b0684fdbad55111dad2
Autor:
Yu Sakurai, Himeka Watanabe, Kazuma Nishio, Kohei Hashimoto, Atsuki Harada, Masaki Gomi, Masayoshi Suzuki, Ryotaro Oyama, Takumi Handa, Risa Sato, Hina Takeuchi, Ryoga Taira, Kenta Tezuka, Kota Tange, Yuta Nakai, Hidetaka Akita, Yasuo Uchida
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1560 (2022)
The blood–brain barrier (BBB), which is comprised of brain capillary endothelial cells, plays a pivotal role in the transport of drugs from the blood to the brain. Therefore, an analysis of proteins in the endothelial cells, such as transporters an
Externí odkaz:
https://doaj.org/article/8ef28c83ac23478d96d8b2a64e93136b
Autor:
Hiroki Tanaka, Ryo Miyama, Yu Sakurai, Shinya Tamagawa, Yuta Nakai, Kota Tange, Hiroki Yoshioka, Hidetaka Akita
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2097 (2021)
(1) Background: T cells are important target cells, since they exert direct cytotoxic effects on infected/malignant cells, and affect the regulatory functions of other immune cells in a target antigen-specific manner. One of the current approaches fo
Externí odkaz:
https://doaj.org/article/dd8bd9318b14419e841f43ab5e4c4e99
Autor:
Hiroki Tanaka, Nae Takata, Yu Sakurai, Tokuyuki Yoshida, Takao Inoue, Shinya Tamagawa, Yuta Nakai, Kota Tange, Hiroki Yoshioka, Masatoshi Maeki, Manabu Tokeshi, Hidetaka Akita
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 544 (2021)
The world-first success of lipid nanoparticle (LNP)-based siRNA therapeutics (ONPATTRO®) promises to accelerate developments in siRNA therapeutics/gene therapy using LNP-type drug delivery systems (DDS). In this study, we explore the optimal composi
Externí odkaz:
https://doaj.org/article/30d57eeba6e3433dadd085df9e3458c3
Autor:
Hiroki Tanaka, Shinya Hagiwara, Daiki Shirane, Takuma Yamakawa, Yuka Sato, Chika Matsumoto, Kota Ishizaki, Miho Hishinuma, Katsuyuki Chida, Kasumi Sasaki, Etsuo Yonemochi, Keisuke Ueda, Kenjirou Higashi, Kunikazu Moribe, Takashi Tadokoro, Katsumi Maenaka, Sakura Taneichi, Yuta Nakai, Kota Tange, Yu Sakurai, Hidetaka Akita
Publikováno v:
ACS Nano. 17:2588-2601
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e53e3086f300ad65090cc8a37bddfbab
https://doi.org/10.1021/acsnano.2c10501
https://doi.org/10.1021/acsnano.2c10501
Autor:
Akita, Daiki Shirane, Hiroki Tanaka, Yu Sakurai, Sakura Taneichi, Yuta Nakai, Kota Tange, Itsuko Ishii, Hidetaka
Publikováno v:
Pharmaceutics; Volume 15; Issue 7; Pages: 1819
The lipid nanoparticle (LNP) is one of the promising nanotechnologies for the delivery of RNA molecules, such as small interfering RNA (siRNA) and messenger RNA (mRNA). A series of LNPs that contain an mRNA encoding the antigen protein of SARS-CoV-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::1d811ef79dd0b8bd96ca1c6cc48e3887